Peptides for sleep: separating signal from TikTok hype

What did @conciergemd actually say?

Dr. Sogol Ash, identified as a functional medicine and longevity physician at Concierge MD, made two specific peptide claims in this video. She said DSIP, which stands for Delta Sleep-Inducing Peptide, helps the brain "spend more time in deep, restorative sleep" by supporting sleep quality rather than just sleep onset. She also said Epithalon supports circadian rhythm regulation and is "especially helpful for people whose internal clocks are off from things like stress, travel, or aging." Neither peptide is FDA-approved, and both exist in a regulatory gray zone for clinical use.

To her credit, she framed these as research-backed options rather than cures, and she grounded her pitch in a reasonable premise: sleep is when the body repairs itself. That framing is accurate. The question is whether DSIP and Epithalon actually do what she says they do.

Does the science back this up?

For DSIP, the research is older and thinner than most peptide advocates admit. The original work was done decades ago. Specifically, Schoenenberger et al. (1977, Pflügers Archiv) identified DSIP as a sleep-modulating peptide in rabbits. Human evidence is sparse and methodologically weak. A handful of small trials in the 1980s and 1990s showed some delta-wave sleep activity changes, but nothing that meets modern standards of evidence. The claim that it helps the brain spend more time in deep sleep is plausible in theory, but not robustly proven in humans.

For Epithalon (also spelled Epitalon), the most-cited research comes from Vladimir Khavinson and colleagues, who have published extensively on this tetrapeptide's effects on the pineal gland and melatonin production. Khavinson et al. (2012, Bulletin of Experimental Biology and Medicine) reported circadian rhythm improvements in aging subjects. The circadian rhythm angle Dr. Ash describes is at least grounded in the existing mechanistic literature, even if that literature is limited in scale and largely Russian in origin, which introduces some replication concerns.

What did they get wrong (or right)?

The functional medicine framing she opens with, that sleep is when the body "repairs, detoxes, balances hormones, and resets your nervous system," is broadly accurate. Sleep-dependent memory consolidation, glymphatic clearance, and HPA axis regulation are well-documented. Walker (2017, Why We Sleep, Scribner) and Xie et al. (2013, Science) on glymphatic function support this general picture. She gets credit for not overselling the mechanism here.

Where things get slippery is in the specificity of her peptide claims. Saying DSIP has been "studied for" an effect is doing a lot of work. It has been studied. The studies are small, old, and not replicated at scale. Saying Epithalon has "been studied more for circadian rhythm regulation" is technically true but implies a more robust evidence base than actually exists. The research community has not converged on these peptides as established sleep aids. Presenting them as if the science is settled, even softly, is a stretch.

She did not prescribe doses or claim these peptides cure insomnia or any diagnosable sleep disorder. That restraint matters and keeps her claims from crossing into outright misinformation territory.

What should you actually know?

Both DSIP and Epithalon are bioactive peptides with mechanistic rationale for sleep-related effects, but neither has been validated in large, randomized, controlled human trials. If you are considering either for sleep, a few things are worth understanding.

• DSIP research peaked in the 1980s. The hypothesis is interesting; the clinical evidence is not strong enough to call this an established therapy.
• Epithalon's most-cited research is from a single research group in Russia. Independent replication in Western peer-reviewed journals is limited.
• Neither peptide is FDA-approved. Compounded versions are available through some telehealth platforms, but compounded peptides are not equivalent to tested pharmaceutical products.
• Existing sleep interventions with far stronger evidence include CBT-I (cognitive behavioral therapy for insomnia), melatonin for circadian phase issues, and addressing underlying conditions like sleep apnea. These should not be bypassed in favor of peptides without a proper clinical evaluation.

If you are working with a physician on sleep optimization, asking about these peptides is not unreasonable. But going in with realistic expectations about how limited the evidence actually is matters.

Bottom line: should you trust this video?

Dr. Ash is more careful than the average peptide influencer. She did not promise miracle sleep, did not prescribe doses, and accurately noted that sleep is foundational to health. But the video still presents a rosier picture of the evidence for DSIP and Epithalon than the actual literature supports. This is a common problem in functional medicine content: real mechanistic science gets used to imply clinical proof that does not yet exist. The peptides might be worth discussing with a knowledgeable physician. The science, as presented here, is being rounded up a bit.